About 12 results found for searched term "Complement factor I" (0.132 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M22490 | Recombinant Human C1QTNF1 Protein (HEK293, C-6His) | Cytokines and Growth Factors |
| Complement C1q Tumor Necrosis Factor-Related Protein 1 | ||
| C1QTNF1 is a secreted protein，contains 1 C1q domain and 1 collagen-like domain. C1QTNF1 is a novel adipokine, providing a significant framework to further address the physiological functions and mechanisms of the action of this family of secreted glycoproteins in normal and disease states. C1QTNF1 increases the production of aldosterone. | ||
| M28303 | Complement factor D-IN-1 | Complement System |
| Complement factor D-IN-1 is a potent and selective small-molecule reversible factor d inhibitor, with IC50s of 0.006 and 0.05 μM in FD Thioesterolytic Fluorescent Assay and a MAC Deposition Assay, respectively. | ||
| M29009 | Complement factor D-IN-2 | Complement System |
| Complement factor D-IN-2 is an inhibitor of complement factor D. Complement factor D-IN-2 targets factor D and inhibits the complement cascade at an early and essential point in the alternative complement pathway. Complement factor D-IN-2 can be used for the research of autoimmune diseases. | ||
| M52596 | Complement factor I | Metabolite/Endogenous Metabolite |
| Complement factor I is a serine protease that downregulates complement activity in the fluid phase and/or on cell surfaces. | ||
| M10145 | Danicopan (ALXN2040) | Complement System |
| ACH-4471; ACH-0144471; ALXN2040 | ||
| Danicopan (ALXN2040, ACH-4471, ACH-0144471) is a first-in-class, potent, selective, orally active inhibitor of complement factor D with a Kd value of 0.54 nM for human Factor D. Danicopan can Selectively inhibits key complement factor D in the alternative pathway, blocking C3 convertase production and inhibiting alternative pathway activity. It also prevents the deposition of C3b fragments on blood erythrocytes and inhibits erythrocyte catabolism and extravascular hemolysis. | ||
| M10317 | LNP023 hydrochloride (Iptacopan HCl) | Complement System |
| Iptacopan hydrochloride | ||
| Iptacopan (LNP023) hydrochloride is a first-in-class orally bioavailable, highly potent and selective complement factor B inhibitor with an IC50 value of 10 nM. | ||
| M11511 | Vemircopan | Complement System |
| ALXN2050; ACH 0145228; ACH-5228 | ||
| Vemircopan (ALXN2050) is an oral active complement factor D (FD) inhibitor. | ||
| M21386 | Pelecopan | Complement System |
| BCX9930 | ||
| Pelecopan (BCX9930) is a potent, selective complement factor D inhibitor with oral activity and an IC50 value of 14.3 nM. | ||
| M24600 | Lampalizumab | Complement System |
| RG 7417; TNX 234; Anti-CFD Recombinant Antibody | ||
| Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research. | ||
| M50312 | Complement factor D | Enzymes & Coenzymes |
| Complement factor D is a biochemical reagent that can be used as a biological material or organic compound for life science related research. | ||
| M54080 | POT-4 | Complement System |
| POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. | ||
| M55560 | Avacincaptad pegol sodium | Complement System |
| ARC1905 | ||
| Avacincaptad pegol (ARC1905) is an anti-C5 RNA aptamer that inhibits the cleavage of complement factor 5 (C5) into C5a and C5b. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
